ClinicalTrials.gg
RecruitingNCT06414005Updated Jun 5, 2024

A Phase 2b/3 Study of TPX-115 on Partial-thickness Rotator Cuff Tear

A Phase 2/3 interventional study of TPX-115 and Placebo (Saline) in Partial Thickness Rotator Cuff Tear, sponsored by Tego Science, Inc.. Recruiting at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-06-05.

Sponsored by Tego Science, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of — 3 open to participants now, 4 under way, 1 of them phase 3. Rotator Cuff Injuries · Korea, Republic of.

Planned enrollment
Largest of 25
166 · median 74
Started
2024
with 1 other
Phase 2/3
Only one
of the 30
Registered
23rd of 30
by date
Lead sponsor
3 of 30
Tego Science, Inc.

Among the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 2/3, and was the 23rd registered.

Rotator Cuff Injuries

631 studies on the registry are indexed under Rotator Cuff Injuries; 156 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

3 of the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Rotator cuff tear is one of the most common shoulder diseases and conservative treatment is commonly used for tears involving ≤50% of tendon thickness. Since conventional conservative treatments are not fundamental to repair tendon tissue, there is a growing need of new therapy to improve structural outcome. This study assesses the safety and efficacy of allogeneic fibroblasts on partial-thickness rotator cuff tear. The primary outcome is change in Constant Score (CS) at 24 weeks after TPX-115 injection. Secondary outcomes include changes from baseline in CS, Visual Analogue Score (VAS) pain score, American Shoulder and Elbow Surgeons (ASES) score, Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH), Simple Shoulder Test (SST), and functional evaluations including Range of Motion (ROM) at 4, 12, 24 and 52 weeks after administration and structural evaluation using MRI at 24 and 52 weeks after injection.

03

Conditions studied

  • Partial Thickness Rotator Cuff Tear

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 19 years of age or older.
  2. Have partial-thickness rotator cuff tear, ≤50% of tendon thickness or of Ellman grade II assessed by MRI.
  3. Have unilateral shoulder pain, muscle weakness and limited active range of motion lasting more than 3 months despite conservative treatment
  4. VAS pain score ≥4 at screening.
  5. Understand fully the study and voluntarily sign the for participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Regardless of partial-thickness rotator cuff tear, have full-thickness rotator cuff tear confirmed by MRI.
  2. Have been treated with the following

    • Have had painkiller within 1 week prior to screening visit.
    • Have had received systemic or agents within 4 weeks prior to screening visit.
    • Have had subacromial or intra-articular injections on the affected shoulder within 3 months prior to screening visit.
    • Have shoulder surgery on the rotator cuff tear or had received drug that included growth factor, within 6 months prior to screening visit.
  3. Have been diagnosed with the following diseases.

    • Inflammatory joint diseases
    • Other shoulder diseases which may cause shoulder pain or functional disorder
    • diseases
    • Active or C
    • Ab positive
    • Malignant tumors within the last 5 years
    • Coagulopathy
    • Genetic disorders related to fibroblasts of collagen
    • Other serious diseases deemed to affect the results of the study
  4. Have allergies to bovine proteins or gentamicin.
  5. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of suggested in this study.
  6. Have participated in other clinical trials and received agents within 4 weeks of this study.
  7. Be deemed inadequate for the study by investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    TPX-115

    Subjects receive ultrasound-guided intratendinous injection of TPX-115

    Biological: TPX-115

  • Placebo comparator
    Placebo (Saline)

    Subjects receive ultrasound-guided intratendinous placebo injection

    Other: Placebo (Saline)

Interventions

  • BiologicalTPX-115

    Ultrasound-guided intratendinous injection of allogeneic fibroblasts (TPX-115)

  • OtherPlacebo (Saline)

    Ultrasound-guided intratendinous placebo injection

06

What researchers measure

Primary outcomes

  1. Change in shoulder score of Constant score (CS)

    The CS total score (100) = Pain (15) + Activity of Daily Living (20) + Mobility (40) + Strength(25)

    Time frame: 24 weeks

Secondary outcomes

  1. Change in shoulder score of Constant score (CS)

    The CS total score (100) = Pain (15) + Activity of Daily Living (20) + Mobility (40) + Strength(25).

    Time frame: 4, 12, 52 weeks

  2. hange in pain score of Visual Analogue Scale (VAS)

    VAS pain score is measured on a scale of 0 (no pain) to 10 (worst pain imaginable).

    Time frame: 4, 12, 24, 52 weeks

  3. Change of American Shoulder and Elbow Surgeons (ASES) Shoulder Score

    ASES shoulder score is derived from the visual analogue scale score for pain and the activities of daily living score. The total score(100 maximum points) is weighted 50% for pain and 50% for function.

    Time frame: 4, 12, 24, 52 weeks

  4. Change of Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH) Outcome Measure

    The QuickDASH is a shortened version of the DASH Outcome Measure. Instead of 30 items, the QuickDASH uses 11 items to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb.

    Time frame: 4, 12, 24, 52 weeks

  5. Change in Simple Shoulder Test (SST) Score

    SST assesses functional disability of the shoulder (function related to pain, function/strength and Range of Motion).

    Time frame: 4, 12, 24, 52 weeks

  6. Change in Range of Motion (ROM)

    Measurement of ROM for forward elevation, external rotation at 90º abduction, external rotation at side and internal rotation at back.

    Time frame: 4, 12, 24, 52 weeks

  7. Change in Ellman grade on Magnetic Resonance Image (MRI)

    Ellman grade is assessed by an independent evaluator.

    Time frame: 24, 52 weeks

  8. Change of tendinosis on MRI

    Tendinosis is assessed with tendinosis grading system by an independent evaluator. (0: normal, 1: mild, 2: moderate, 3: marked)

    Time frame: 24, 52 weeks

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jun 2026, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 14, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jan 31, 2027
Last update
Jun 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06414005
Lead sponsor
Tego Science, Inc.
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Apr 15, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 5, 2024

Study contacts

Jikhyon Han, Ph.D.
Contact
jhhan@tegoscience.com
+82-2-818-2900
Joo Han Oh, M.D.
principal investigator · Seoul National University Bundang Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TPX-115

Start the discussion